Expert Review of Clinical Pharmacology最新文献_第6页

Clinical considerations and pharmacokinetic interactions between HIV and tuberculosis therapeutics. 临床考虑因素和艾滋病毒与结核病治疗药物之间的药代动力学相互作用。

IF 3.6 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2024-07-01 Epub Date: 2024-02-14 DOI: 10.1080/17512433.2024.2317954

Nicole F Maranchick, Awewura Kwara, Charles A Peloquin

{"title":"Clinical considerations and pharmacokinetic interactions between HIV and tuberculosis therapeutics.","authors":"Nicole F Maranchick, Awewura Kwara, Charles A Peloquin","doi":"10.1080/17512433.2024.2317954","DOIUrl":"10.1080/17512433.2024.2317954","url":null,"abstract":"Introduction: Tuberculosis (TB) is a leading infectious disease cause of mortality worldwide, especially for people living with human immunodeficiency virus (PLWH). Treating TB in PLWH can be challenging due to numerous drug interactions.Areas covered: This review discusses drug interactions between antitubercular and antiretroviral drugs. Due to its clinical importance, initiation of antiretroviral therapy in patients requiring TB treatment is discussed. Special focus is placed on the rifamycin class, as it accounts for the majority of interactions. Clinically relevant guidance is provided on how to manage these interactions. An additional section on utilizing therapeutic drug monitoring (TDM) to optimize drug exposure and minimize toxicities is included.Expert opinion: Antitubercular and antiretroviral coadministration can be successfully managed. TDM can be used to optimize drug exposure and minimize toxicity risk. As new TB and HIV drugs are discovered, additional research will be needed to assess for clinically relevant drug interactions.","PeriodicalId":12207,"journal":{"name":"Expert Review of Clinical Pharmacology","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139716002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

What is novel in the clinical management of pemphigus vulgaris? 寻常型天疱疮的临床治疗有何新意？

IF 4.4 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2024-05-01 Epub Date: 2024-05-12 DOI: 10.1080/17512433.2024.2350943

Ahmad Vafaeian, Hamidreza Mahmoudi, Maryam Daneshpazhooh

{"title":"What is novel in the clinical management of pemphigus vulgaris?","authors":"Ahmad Vafaeian, Hamidreza Mahmoudi, Maryam Daneshpazhooh","doi":"10.1080/17512433.2024.2350943","DOIUrl":"10.1080/17512433.2024.2350943","url":null,"abstract":"Introduction: Pemphigus, an uncommon autoimmune blistering disorder affecting the skin and mucous membranes, currently with mortality primarily attributed to adverse reactions resulting from treatment protocols. Additionally, the existing treatments exhibit a notable recurrence rate. The high incidence of relapse and the considerable adverse effects associated with treatment underscore the imperative to explore safer and more effective therapeutic approaches. Numerous potential therapeutic targets have demonstrated promising outcomes in trials or preliminary research stages. These encompass anti-CD-20 agents, anti-CD-25 agents, TNF-α inhibition, FAS Ligand Inhibition, FcRn inhibition, BAFF inhibition, Bruton's tyrosine kinase (BTK) inhibition, CAAR T Cells, JAK inhibition, mTOR inhibition, abatacept, IL-4 inhibition, IL-17 inhibition, IL-6 inhibition, polyclonal Regulatory T Cells, and autologous hematopoietic stem cell transplantation.Areas covered: The most significant studies regarding the impact and efficacy of the mentioned treatments on pemphigus were meticulously curated through a comprehensive search conducted on the PubMed database. Moreover, the investigations of interest cited in these studies were also integrated.Expert opinion: The efficacy and safety profiles of the other treatments under discussion do not exhibit the same level of robustness as anti-CD20 therapy, which is anticipated to endure as a critical element in pemphigus treatment well into the foreseeable future.","PeriodicalId":12207,"journal":{"name":"Expert Review of Clinical Pharmacology","volume":null,"pages":null},"PeriodicalIF":4.4,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140861870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Therapeutic drug monitoring in kidney and liver transplantation: current advances and future directions. 肝肾移植中的治疗药物监测：当前进展与未来方向。

IF 4.4 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2024-05-01 Epub Date: 2024-05-16 DOI: 10.1080/17512433.2024.2354276

Béni Ntobe-Bunkete, Florian Lemaitre

{"title":"Therapeutic drug monitoring in kidney and liver transplantation: current advances and future directions.","authors":"Béni Ntobe-Bunkete, Florian Lemaitre","doi":"10.1080/17512433.2024.2354276","DOIUrl":"10.1080/17512433.2024.2354276","url":null,"abstract":"Introduction: Immunosuppressive drugs (ISD) present a narrow therapeutic window and extremely high inter- and intra-individual pharmacokinetic variability, which complicates their use in solid organ transplant recipients. In order to find a narrow appropriate equilibrium for each patient with the aim of maintaining clinical efficacy and reducing the risk of adverse drug reactions, a complex both clinical and biological monitoring is required, in particular through the use of therapeutic drug monitoring (TDM).Area covered: This review provides an overview of the available information on the relationship between exposure to immunosuppressive drugs and their efficacy and/or toxicity in kidney and liver transplantation. The aim of the review is to describe the pharmacodynamic/pharmacokinetic relationship that exists for immunosuppressive drugs, to summarize the studies that assess the value of TDM for these drugs in clinical practice, and to present the target and monitoring strategies aimed at optimizing patient immunosuppression, which could help to take a step forward in the field of solid organ transplant patient care.Expert opinion: To improve the care of transplant patients, several TDM innovations can be pursued by investigators. Among these, the development of microsampling methods for TDM or the combination of pharmacodynamic biomarkers with ISD exposure measurements appear to be relevant strategies.","PeriodicalId":12207,"journal":{"name":"Expert Review of Clinical Pharmacology","volume":null,"pages":null},"PeriodicalIF":4.4,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140897754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Genito-urinary infectious adverse events related to sodium glucose cotransporter-2 inhibitors: a network meta-analysis and meta-regression. 与钠葡萄糖共转运体-2抑制剂相关的泌尿生殖系统感染不良事件：网络荟萃分析和荟萃回归。

IF 4.4 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2024-05-01 Epub Date: 2024-05-16 DOI: 10.1080/17512433.2024.2355287

Kannan Sridharan, Gowri Sivaramakrishnan

{"title":"Genito-urinary infectious adverse events related to sodium glucose cotransporter-2 inhibitors: a network meta-analysis and meta-regression.","authors":"Kannan Sridharan, Gowri Sivaramakrishnan","doi":"10.1080/17512433.2024.2355287","DOIUrl":"10.1080/17512433.2024.2355287","url":null,"abstract":"Introduction: Sodium glucose cotransporter-2 inhibitors (SGLT2is) are an emerging class of drugs with wide indications. Controversial evidence exists regarding the risk of urinary tract infection (UTI) and genital infections (GI) with SGLT2is paving way for undertaking this network meta-analysis and meta-regression study.Methods: Data from randomized trials evaluating SGLT2is reporting the number of patients with UTI and GI were included. Odds ratios (OR) with 95% confidence intervals (95% CI) were the effect estimates. Meta-regression analysis identified risk factors. Number needed to harm (NNH) was estimated.Results: Two hundred and sixty-four articles were included [UTI (213 studies; 150,140 participants) and GI (188 studies; 121,275 participants)]. An increased risk of UTI (OR: 1.11; 95% CI: 1.06, 1.16) and GI (OR: 3.5, 95% CI: 3.1, 3.9) was observed. Men showed a lower risk of UTI (OR: 0.2; 95% CI: 0.2, 0.3) and GI (OR: 0.4; 95% CI: 0.4, 0.5). Meta-regression analyses revealed BMI ≥ 30 kg/m2 and duration of SGLT2i treatment for ≥6 months as risk factors. NNH was 16 for UTI and 25 for GI.Conclusion: SGLT2is increase the risk of UTI and GI that needs to be incorporated in the treatment guidelines with precautions in high-risk patients.Prospective protocol registration: https://osf.io/5fwyk.","PeriodicalId":12207,"journal":{"name":"Expert Review of Clinical Pharmacology","volume":null,"pages":null},"PeriodicalIF":4.4,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140907911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The thiazide-like diuretic chlorthalidone as an alternative evidence-based therapy for resistant hypertension in patients with stage 4 chronic kidney disease. 将噻嗪类利尿剂氯塞酮作为慢性肾脏病 4 期患者耐药性高血压的替代循证疗法。

IF 4.4 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2024-05-01 Epub Date: 2024-03-22 DOI: 10.1080/17512433.2024.2333776

Panagiotis I Georgianos, Vasilios Vaios, Ioannis Kontogiorgos, Maria Divani, Vassilios Liakopoulos

引用次数: 0

Reducing potentially inappropriate polypharmacy at a national and international level: the impact of deprescribing networks. 在国家和国际层面减少潜在的不当多药使用：处方网络的影响。

IF 4.4 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2024-05-01 Epub Date: 2024-05-20 DOI: 10.1080/17512433.2024.2355270

Emily G McDonald, Carina Lundby, Wade Thompson, Cynthia Boyd, Barbara Farrell, Camille Gagnon, Jennie Herbin, Ninh Khuong, Frank Moriarty, Tiphaine Pierson, Sion Scott, Ian A Scott, Jim Silvius, Anne Spinewine, Michael A Steinman, Cara Tannenbaum, Johanna Trimble, Justin P Turner, Emily Reeve

{"title":"Reducing potentially inappropriate polypharmacy at a national and international level: the impact of deprescribing networks.","authors":"Emily G McDonald, Carina Lundby, Wade Thompson, Cynthia Boyd, Barbara Farrell, Camille Gagnon, Jennie Herbin, Ninh Khuong, Frank Moriarty, Tiphaine Pierson, Sion Scott, Ian A Scott, Jim Silvius, Anne Spinewine, Michael A Steinman, Cara Tannenbaum, Johanna Trimble, Justin P Turner, Emily Reeve","doi":"10.1080/17512433.2024.2355270","DOIUrl":"10.1080/17512433.2024.2355270","url":null,"abstract":"Introduction: Over the past decade, polypharmacy has increased dramatically. Measurable harms include falls, fractures, cognitive impairment, and death. The associated costs are massive and contribute substantially to low-value health care. Deprescribing is a promising solution, but there are barriers. Establishing a network to address polypharmacy can help overcome barriers by connecting individuals with an interest and expertise in deprescribing and can act as an important source of motivation and resources.Areas covered: Over the past decade, several deprescribing networks were launched to help tackle polypharmacy, with evidence of individual and collective impact. A network approach has several advantages; it can spark interest, ideas and enthusiasm through information sharing, meetings and conversations with the public, providers, and other key stakeholders. In this special report, the details of how four deprescribing networks were established across the globe are detailed.Expert opinion: Networks create links between people who lead existing and/or budding deprescribing practices and policy initiatives, can influence people with a shared passion for deprescribing, and facilitate sharing of intellectual capital and tools to take initiatives further and strengthen impact.This report should inspire others to establish their own deprescribing networks, a critical step in accelerating a global deprescribing movement.","PeriodicalId":12207,"journal":{"name":"Expert Review of Clinical Pharmacology","volume":null,"pages":null},"PeriodicalIF":4.4,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140916060","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Is a low dose of dexamethasone sufficient to prevent paclitaxel-related hypersensitivity reactions? A retrospective study in patients with gynecologic malignancy. 小剂量地塞米松足以预防紫杉醇相关超敏反应吗？一项针对妇科恶性肿瘤患者的回顾性研究。

IF 4.4 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2024-04-23 DOI: 10.1080/17512433.2024.2343852

Di Xiao, Zhiyun Yang, Yin Shi, Wenqing Yang, Yu Zhang

{"title":"Is a low dose of dexamethasone sufficient to prevent paclitaxel-related hypersensitivity reactions? A retrospective study in patients with gynecologic malignancy.","authors":"Di Xiao, Zhiyun Yang, Yin Shi, Wenqing Yang, Yu Zhang","doi":"10.1080/17512433.2024.2343852","DOIUrl":"https://doi.org/10.1080/17512433.2024.2343852","url":null,"abstract":"BACKGROUND\u0000Paclitaxel hypersensitivity reactions (HSRs) are prevalent, especially in females. The common paclitaxel pretreatment, dexamethasone, may inhibit chemotherapy efficacy and accelerate tumor progression. We aimed to balance paclitaxel HSRs and the lowest dexamethasone dose for gynecologic malignancies.\u0000\u0000\u0000METHODS\u0000We retrospectively examined 1,074 cycles of 3-weekly paclitaxel-containing treatment for 231 gynecologic malignancies at Xiangya Hospital. HSR incidence with different dexamethasone regimens was the primary outcome. Risk factors were examined in all cycles using univariate and multivariate models with generalized estimating equations. A subgroup analysis of initial exposure to paclitaxel was also conducted.\u0000\u0000\u0000RESULTS\u0000HSR occurred in 33 patients (14.29%) and 49 cycles (4.56%), including 69.39% in cycles 1-2. There were no severe HSRs (grade ≥3). Different premedication regimens, including dexamethasone dosage and route, ranitidine presence or absence, didn't affect HSR incidence in univariate and multivariate analyzes (p > 0.05). Premenopausal women exerted fewer HSRs (ORadj 0.22, 95%CI 0.08-0.58; p = 0.002). At the first exposure to paclitaxel, more than 10 mg of dexamethasone didn't diminish HSRs (OR 0.83, 95%CI 0.27-2.59; p = 0.753).\u0000\u0000\u0000CONCLUSIONS\u0000In gynecologic malignancies, 10 mg dexamethasone along with 20 mg diphenhydramine may be adequate to prevent paclitaxel HSRs without ranitidine. It is necessary to reevaluate paclitaxel premedication regimens.","PeriodicalId":12207,"journal":{"name":"Expert Review of Clinical Pharmacology","volume":null,"pages":null},"PeriodicalIF":4.4,"publicationDate":"2024-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140668705","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effectiveness of statins in people living with HIV: a systematic review and meta-analysis of randomized controlled trials 他汀类药物对艾滋病毒感染者的疗效：随机对照试验的系统回顾和荟萃分析

IF 4.4 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2024-04-17 DOI: 10.1080/17512433.2024.2344672

Sai Santhosha Mrudula Alla, Dhruv J Shah, Vysakh Ratheesh, Deekshitha Alla, Thanmayee Tummala, Moksh S Khetan, Ritika J Shah, Ruth G Bayeh, Mahek Fatima, Sanah K Ahmed, Mert Sabıroğlu

引用次数: 0

Improvement of assessment in surrogate endpoint and safety outcome of single-arm trials for anticancer drugs 改进抗癌药物单臂试验的替代终点和安全性结果评估

IF 4.4 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2024-04-17 DOI: 10.1080/17512433.2024.2344669

Yafang Huang, Jinqiu Yuan

引用次数: 0

Treatment adherence and adverse event management in chronic lymphocytic leukemia: challenges and strategies for the future 慢性淋巴细胞白血病的治疗依从性和不良事件管理：未来的挑战和战略

IF 4.4 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2024-04-17 DOI: 10.1080/17512433.2024.2344665

Maurlia D. Upchurch, Benyam Muluneh

引用次数: 0